ClinicalTrials.gg
RecruitingNCT07580365Updated Aug 11, 2026

VirtualPark_Pediatric

An interventional study of Dual-task cycling and Standard therapy in Dystrophinopathy, Muscular Dystrophies and Congenital Myopathies, sponsored by Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato. Recruiting at 4 sites in Italy. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Muscular Dystrophies with a site in Italy — 6 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophies · Italy.

Planned enrollment
19th of 24
22 · median 56
Started
2026
with 2 others
No phase
9 of 31
4 open now
Registered
30th of 31
by date

Among the 31 studies in Muscular Dystrophies with a site in Italy, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 30th registered.

Muscular Dystrophies

224 studies on the registry are indexed under Muscular Dystrophies; 48 are open to participants now.

Browse Muscular Dystrophies studies →

Open to participants now

6 of the 31 studies in Muscular Dystrophies with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 38 Muscular Dystrophies studies recruiting now, 14 (37%) set no upper age limit and 15 (39%) stop at 75 or younger; 24 take children under 18; 7 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Muscular Dystrophies with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the effects of a dual-task, multimodal training program on slowing functional motor decline in children and adolescents with neuromuscular disorders. The main questions it aims to answer are:

Does Virtual Park slow functional motor decline in children and adolescents with neuromuscular diseases compared with standard therapy?

Does Virtual Park contribute to increased engagement and improved neuropsychological function?

If there is a comparison group, Researchers will compare dual-task cycling supported by the Virtual Park application to standard therapy to see whether it improves motor and neuropsychological functions and engagement.

Participants will undergo two phases:

  • Phase 1: 3 months of standard therapy;
  • Phase 2: 3 months of experimental conditions in which patients undergo a rehabilitative intervention with Virtual Park, 3 times a week.
03

Conditions studied

  • Dystrophinopathy
  • Muscular Dystrophies
  • Congenital Myopathies

Keywords

  • Sports for Persons with Disabilities
  • Rehabilitation
  • Neuromuscular Diseases
  • Dual-Task Exercises
  • Virtual Reality
  • Children with Disabilities
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • availability of a definitive clinical or molecular genetic diagnosis of a neuromuscular disease;
  • age between 6 years and 17 years and 11 months (inclusive);
  • height compatible with the use of the Thera-Trainer (minimum 120 cm);
  • performance Upper Limb Module 2.0 assessment: Entry level >= 2

Exclusion criteria

Exclusion Criteria:

  • other concomitant genetic diseases;
  • presence of visual impairments that prevent access to the experimental virtual reality protocol;
  • concomitant compromised cardio-respiratory function that contraindicates cycle ergometer training;
  • severe osteoporosis.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Two-phase arm

    * Phase 1: 3 months of standard therapy; * Phase 2: 3 months of experimental conditions in which patients undergo a rehabilitative intervention with Virtual Park, 3 times a week for 20 minutes (plus 5-10 minutes of warm-up and 5-10 minutes of cool down).

    Device: Dual-task cycling · Other: Standard therapy

Interventions

  • DeviceDual-task cycling

    VirtualPark is a software application connecting to a medical certified cycle/arm ergometer (i.e., TheraTrainer TIGO). The application allows for dual task training. In particular, while cycling, participants can perform one of four different available exercises. Each exercise is focused on a specific cognitive domain: Task 1: visual attention, inhibition and cognitive flexibility; Task 2: working memory; Task 3: inhibition; Task 4: navigation.

  • OtherStandard therapy

    Participants undergo their standard plan: outpatient treatment, if planned, or no treatment.

06

What researchers measure

Primary outcomes

  1. Motor Function Measure-32 (MFM-32) - Total score

    The Motor Function Measure-32 is a motor skills assessment scale validated for patients affected by neuromuscular pathology from 6 years of age. The instrument consists of 32 items (scored from 0 to 3) divided into 3 dimensions: D1- standing position and transfers (13 items), D2- axial and proximal motor skills (12 items) and D3- distal motor skills (7 items). The results are expressed as a percentage in relation to the maximum score. The result of each dimension corresponds to the sum of the scores obtained by the subject in the items of this dimension divided by the maximum score of the same dimension and multiplied by 100. For the MFM-32 the total score corresponds to the sum of all the scores attributed to the subject (all dimensions together) divided by 96 and multiplied by 100.

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

Secondary outcomes

  1. North Star Ambulatory Assessment (NSSA)

    \[FOR AMBULATORY PARTICIPANTS ONLY\] The North Star Ambulatory Assessment (NSSA) scale was developed specifically for ambulatory children with dystrophinopathy starting at age 5 to obtain information on their motor and functional abilities. The instrument consists of 17 items scored from 0 to 2. The final score is the sum of the scores obtained for all items. Two timed tests are also recorded: the time to stand up from the ground and the time required to walk/run 10 meters.

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

  2. Timed functional tests (TFTs)

    \[FOR AMBULATORY PARTICIPANTS ONLY\] Timed functional tests (TFTs) are administered in a standardized manner to subjects with Duchenne muscular dystrophy to measure the time taken to perform the following four activities: moving from a supine to a standing position, walking/running for 10 meters, and ascending and descending a standardized 4-step staircase. The scoresheet records, in addition to the time taken to complete the task, a qualitative grading score from 1 to 6.

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

  3. 6-Minute Walking Test (6MWT)

    \[FOR AMBULATORY PARTICIPANTS ONLY\] The 6-Minute Walking Test (6MWT) was developed in the cardio-respiratory field but is now used across various fields of motor rehabilitation where it is necessary to quantify the patient's walking endurance. The test measures the distance a patient can cover, walking on a flat surface along a standardized path, in a period of 6 minutes \[25\]. In addition to the total distance covered, the distances covered for each minute are also collected and any falls/pauses are recorded.

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

  4. Performance Upper Limb Module 2.0 scale (PUL version 2.0)

    \[FOR NON-AMBULATORY PARTICIPANTS ONLY\] The Performance Upper Limb Module 2.0 scale (PUL version 2.0) was developed to evaluate the motor performance of the upper limbs of subjects with dystrophinopathies from 5 years of age. This latest version of the instrument consists of an entry item useful for defining the patient's functional level and scored separately (from 0 to 6) and of 22 other items (scored from 0 to 2). The final score is made up of 2 values: the entry level score and the total score given by the sum of the scores obtained in the individual items \[26\].

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

  5. Assisted-6 Minute Cycling Test (A6MWT)

    Performance change in the Assisted 6-minute cycling test (A6MCT). The A6MCT is a submaximal endurance test performed by pedaling with a cycle ergometer in passive mode for both upper and lower limbs, specifically created for subjects affected by Duchenne muscular dystrophy, both ambulatory and non-ambulatory. The final score records the number of complete revolutions performed in 6 minutes; the number of revolutions per minute and any breaks requested by the subject are also recorded \[27\].

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

Other outcomes

  1. NEPSY-II

    The NEPSY-II scale is a battery of tests that allows a neuropsychological evaluation of pediatric subjects, in relation to specific cognitive domains. It is composed of 33 tests that refer to 6 different cognitive domains (Attention and Executive Functions, Language, Memory and Learning, Sensorimotor Functions, Social Perception, Visuospatial Processing). For the purposes of the study, the items "list memory" and "drawing memory" (Memory and Learning domain), the item "Inhibition" (Attention and Executive Functions domain) and the item "find the way" (Visuospatial Processing domain) are used.

    Time frame: Baseline (pre-treatment), 3 months (post-standard therapy, T1), 6 months (post-VirtualPark intervention, T2)

  2. Endurance

    Measurement of heart rate (HR) and heart rate variability (HRV) collected with a wearable sensor (chest band), Movesense Medical (class IIa MDR 2017/745) or comparable medically certified device.

    Time frame: Continuously assessed during each training session from Month 3 (T1) to Month 6 (T2).

  3. User Engagement Scale-Short Form (UES-SF)

    The User Engagement Scale-Short Form (UES-SF) questionnaire will be used to measure engagement. It is a self-report questionnaire, composed of 12 items rated on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree). In particular, the UES-SF questionnaire investigates the following four factors: perceived usability, aesthetic appeal, focused attention, and reward. This questionnaire will be administered to the study participants in the Italian version, for which the scale has been translated and validated.

    Time frame: Every week (i.e., every 3 sessions) from Month 3 (T1) to Month 6 (T2).

  4. Device safety

    The number and description of any adverse events attributable to the use of the device are collected. Adverse events are monitored in accordance with MDR 2017/745, with events reported to responsible office of the Ministry of Health and the relevant Ethical Committee.

    Time frame: From Month 3 (T1) to Month 6 (T2).

07

Study locations

3 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 46 non-industry interventional studies with no phase under Muscular Dystrophies, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 59. This study's planned 6 months is below that.

Counting every sponsor, half of 48 studies reached it within 33 months; a quarter within 11 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 12, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07580365
Lead sponsor
Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato
Collaborators
IRCCS National Neurological Institute "C. Mondino" Foundation, IRCCS Eugenio Medea, Fondazione Don Carlo Gnocchi ETS, IRCCS Fondazione Stella Maris
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Jun 30, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Sara Arlati, Bioengineer
Contact
sara.arlati@cnr.it
(+39)03412350202

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion